FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs. FluoSphera's technology addresses a critical gap in preclinical drug development by enabling the selection of the best candidate drugs based on their predicted systemic response in humans — ultimately determining clinical success for patients. By accurately predicting drug safety and efficacy, this approach reduces the likelihood of failure during clinical development, improves patient access to effective treatments, and minimizes the need for animal testing.